<?xml version='1.0' encoding='utf-8'?>
<document id="26643335"><sentence text="Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin."><entity charOffset="0-11" id="DDI-PubMed.26643335.s1.e0" text="Clofazimine" /><entity charOffset="109-117" id="DDI-PubMed.26643335.s1.e1" text="Amikacin" /><entity charOffset="122-136" id="DDI-PubMed.26643335.s1.e2" text="Clarithromycin" /><pair ddi="false" e1="DDI-PubMed.26643335.s1.e0" e2="DDI-PubMed.26643335.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26643335.s1.e0" e2="DDI-PubMed.26643335.s1.e1" /><pair ddi="false" e1="DDI-PubMed.26643335.s1.e0" e2="DDI-PubMed.26643335.s1.e2" /><pair ddi="false" e1="DDI-PubMed.26643335.s1.e1" e2="DDI-PubMed.26643335.s1.e1" /><pair ddi="false" e1="DDI-PubMed.26643335.s1.e1" e2="DDI-PubMed.26643335.s1.e2" /></sentence><sentence text="Multidrug therapy is a standard practice when treating infections by nontuberculous mycobacteria (NTM), but few treatment options exist" /><sentence text=" We conducted this study to define the drug-drug interaction between clofazimine and both amikacin and clarithromycin and its contribution to NTM treatment"><entity charOffset="69-80" id="DDI-PubMed.26643335.s3.e0" text="clofazimine" /><entity charOffset="90-98" id="DDI-PubMed.26643335.s3.e1" text="amikacin" /><entity charOffset="103-117" id="DDI-PubMed.26643335.s3.e2" text="clarithromycin" /><pair ddi="false" e1="DDI-PubMed.26643335.s3.e0" e2="DDI-PubMed.26643335.s3.e0" /><pair ddi="false" e1="DDI-PubMed.26643335.s3.e0" e2="DDI-PubMed.26643335.s3.e1" /><pair ddi="false" e1="DDI-PubMed.26643335.s3.e0" e2="DDI-PubMed.26643335.s3.e2" /><pair ddi="false" e1="DDI-PubMed.26643335.s3.e1" e2="DDI-PubMed.26643335.s3.e1" /><pair ddi="false" e1="DDI-PubMed.26643335.s3.e1" e2="DDI-PubMed.26643335.s3.e2" /></sentence><sentence text=" Mycobacterium abscessus and Mycobacterium avium type strains were used" /><sentence text=" Time-kill assays for clofazimine alone and combined with amikacin or clarithromycin were performed at concentrations of 0"><entity charOffset="22-33" id="DDI-PubMed.26643335.s5.e0" text="clofazimine" /><entity charOffset="58-66" id="DDI-PubMed.26643335.s5.e1" text="amikacin" /><entity charOffset="70-84" id="DDI-PubMed.26643335.s5.e2" text="clarithromycin" /><pair ddi="false" e1="DDI-PubMed.26643335.s5.e0" e2="DDI-PubMed.26643335.s5.e0" /><pair ddi="false" e1="DDI-PubMed.26643335.s5.e0" e2="DDI-PubMed.26643335.s5.e1" /><pair ddi="false" e1="DDI-PubMed.26643335.s5.e0" e2="DDI-PubMed.26643335.s5.e2" /><pair ddi="false" e1="DDI-PubMed.26643335.s5.e1" e2="DDI-PubMed.26643335.s5.e1" /><pair ddi="false" e1="DDI-PubMed.26643335.s5.e1" e2="DDI-PubMed.26643335.s5.e2" /></sentence><sentence text="25× to 2× MIC" /><sentence text=" Pharmacodynamic interactions were assessed by response surface model of Bliss independence (RSBI) and isobolographic analysis of Loewe additivity (ISLA), calculating the percentage of statistically significant Bliss interactions and interaction indices (I), respectively" /><sentence text=" Monte Carlo simulations with predicted human lung concentrations were used to calculate target attainment rates for combination and monotherapy regimens" /><sentence text=" Clofazimine alone was bacteriostatic for both NTM"><entity charOffset="1-12" id="DDI-PubMed.26643335.s9.e0" text="Clofazimine" /></sentence><sentence text=" Clofazimine-amikacin was synergistic against M"><entity charOffset="1-12" id="DDI-PubMed.26643335.s10.e0" text="Clofazimine" /><entity charOffset="13-21" id="DDI-PubMed.26643335.s10.e1" text="amikacin" /><pair ddi="false" e1="DDI-PubMed.26643335.s10.e0" e2="DDI-PubMed.26643335.s10.e0" /><pair ddi="false" e1="DDI-PubMed.26643335.s10.e0" e2="DDI-PubMed.26643335.s10.e1" /></sentence><sentence text=" abscessus (I = 0" /><sentence text="41; 95% confidence interval [CI], 0" /><sentence text="29 to 0" /><sentence text="55) and M" /><sentence text=" avium (I = 0" /><sentence text="027; 95% CI, 0"><entity charOffset="9-11" id="DDI-PubMed.26643335.s16.e0" text="CI" /></sentence><sentence text="007 to 0" /><sentence text="048)" /><sentence text=" Based on RSBI analysis, synergistic interactions of 28" /><sentence text="4 to 29" /><sentence text="0% and 23" /><sentence text="2 to 56" /><sentence text="7% were observed at 1× to 2× MIC and 0" /><sentence text="25× to 2× MIC for M" /><sentence text=" abscessus and M" /><sentence text=" avium, respectively" /><sentence text=" Clofazimine-clarithromycin was also synergistic against M"><entity charOffset="1-12" id="DDI-PubMed.26643335.s27.e0" text="Clofazimine" /><entity charOffset="13-27" id="DDI-PubMed.26643335.s27.e1" text="clarithromycin" /><pair ddi="false" e1="DDI-PubMed.26643335.s27.e0" e2="DDI-PubMed.26643335.s27.e0" /><pair ddi="false" e1="DDI-PubMed.26643335.s27.e0" e2="DDI-PubMed.26643335.s27.e1" /></sentence><sentence text=" abscessus (I = 0" /><sentence text="53; 95% CI, 0"><entity charOffset="8-10" id="DDI-PubMed.26643335.s29.e0" text="CI" /></sentence><sentence text="35 to 0" /><sentence text="72) and M" /><sentence text=" avium (I = 0" /><sentence text="16; 95% CI, 0"><entity charOffset="8-9" id="DDI-PubMed.26643335.s33.e0" text="CI" /></sentence><sentence text="04 to 0" /><sentence text="35), RSBI analysis showed 23" /><sentence text="5% and 23" /><sentence text="3 to 53" /><sentence text="3% at 2× MIC and 0" /><sentence text="25× to 0" /><sentence text="5× MIC for M" /><sentence text=" abscessus and M" /><sentence text=" avium, respectively" /><sentence text=" Clofazimine prevented the regrowth observed with amikacin or clarithromycin alone"><entity charOffset="1-12" id="DDI-PubMed.26643335.s43.e0" text="Clofazimine" /><entity charOffset="50-58" id="DDI-PubMed.26643335.s43.e1" text="amikacin" /><entity charOffset="62-76" id="DDI-PubMed.26643335.s43.e2" text="clarithromycin" /><pair ddi="false" e1="DDI-PubMed.26643335.s43.e0" e2="DDI-PubMed.26643335.s43.e0" /><pair ddi="false" e1="DDI-PubMed.26643335.s43.e0" e2="DDI-PubMed.26643335.s43.e1" /><pair ddi="false" e1="DDI-PubMed.26643335.s43.e0" e2="DDI-PubMed.26643335.s43.e2" /><pair ddi="false" e1="DDI-PubMed.26643335.s43.e1" e2="DDI-PubMed.26643335.s43.e1" /><pair ddi="false" e1="DDI-PubMed.26643335.s43.e1" e2="DDI-PubMed.26643335.s43.e2" /></sentence><sentence text=" Target attainment rates of combination regimens were &gt;60% higher than those of monotherapy regimens for M" /><sentence text=" abscessus and M" /><sentence text=" avium" /><sentence text=" The combination of clofazimine with amikacin or clarithromycin was synergistic in vitro"><entity charOffset="20-31" id="DDI-PubMed.26643335.s47.e0" text="clofazimine" /><entity charOffset="37-45" id="DDI-PubMed.26643335.s47.e1" text="amikacin" /><entity charOffset="49-63" id="DDI-PubMed.26643335.s47.e2" text="clarithromycin" /><pair ddi="false" e1="DDI-PubMed.26643335.s47.e0" e2="DDI-PubMed.26643335.s47.e0" /><pair ddi="false" e1="DDI-PubMed.26643335.s47.e0" e2="DDI-PubMed.26643335.s47.e1" /><pair ddi="false" e1="DDI-PubMed.26643335.s47.e0" e2="DDI-PubMed.26643335.s47.e2" /><pair ddi="false" e1="DDI-PubMed.26643335.s47.e1" e2="DDI-PubMed.26643335.s47.e1" /><pair ddi="false" e1="DDI-PubMed.26643335.s47.e1" e2="DDI-PubMed.26643335.s47.e2" /></sentence><sentence text=" This suggests a potential role for clofazimine in treatment regimens that warrants further evaluation"><entity charOffset="36-47" id="DDI-PubMed.26643335.s48.e0" text="clofazimine" /></sentence><sentence text=" " /></document>